Experimental CART123 therapy targets tough blood cancers in early trial

NCT ID NCT06765876

Recruiting now Disease control Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goals are to check safety and find the right dose. Only 18 adults who are also eligible for a stem cell transplant can join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CART123 cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a treatment option for people with hard-to-treat blood cancers like AML or MDS.
What could go wrong: This is a very early, small trial (18 people) focused on safety and dosing. It may not lead to a widely available treatment, and there are risks like severe immune reactions or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myelodysplastic syndrome with excess blasts-2 Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma precursor lymphoblastic lymphoma/leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) LEUKEMIA, MYELOID, ACUTE(AML) MYELODYSPLASTIC SYNDROMES (MDS) PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA

Contacts and locations

Locations

Ustav hematologie a krevni transfuze / Institute of Hematology and Blood Transfusion
RECRUITING

Prague, 12800, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.